Back to results
US 2026/0297175 A1Published application
Anti-il-13 long-acting nanobody sequence and applications thereof
AssigneeShanghai Novamab Biopharmaceuticals Co., Ltd.
InventorsYakun WAN, Min ZHU, Junwei GAI, Guanghui LI
Life of this patent
Estimating the term…
Abstract
An anti-IL-13 long-acting nanobody is provided. A coding sequence encoding the anti-IL-13 nano antibody, a corresponding expression vector, a host cell capable of expressing the nanobody, and a method for producing the nanobody are provided.
Claims21
An anti-IL-13 nanobody, wherein the complementary determining regions (CDRs) of the VHH chain in the nanobody are one or more selected from the group consisting of:
- (1) CDR1 shown in SEQ ID NO:
- 2, CDR2 shown in SEQ ID NO:
- 4, and CDR3 shown in SEQ ID NO:
- 6;
- and
- (2) CDR1 shown in SEQ ID NO:
- 11, CDR2 shown in SEQ ID NO:
- 13, and CDR3 shown in SEQ ID NO:
- 15.
6 more elements
(canceled)
Dependencies are inferred from the claim text.